TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05205759
Drug: Bamlanivimab Etesevimab
Normalized name: Etesevimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
Study: NCT05205759
Drug: Sotrovimab
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
Study: NCT05205759
Drug: Casirivimab-Imdevimab
Normalized name: casirivimab-imdevimab
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
Study: NCT00000961
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04723810
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Study: NCT00021463
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021463
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00021463
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00021463
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05715528
Drug: Obeldesivir
Normalized name: Obeldesivir
DrugBank: Obeldesivir (DB18821)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally without regard to food.
Study: NCT05715528
Drug: Obeldesivir Placebo
DrugBank: Obeldesivir (DB18821)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally without regard to food.
Study: NCT05161468
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
Study: NCT06490341
Drug: GP Regimen, Nimotuzumab, Sintilimab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine,ciplatin, nimotuzumab, sintilimab
Study: NCT05161468
Drug: Protein Rich Plasma(PRP) Injection
Normalized name: plasma protein fraction Injection
DrugBank: Plasma protein fraction (human) (DB13968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
Study: NCT06091657
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT06141031
Drug: TTI-101
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
Study: NCT05694260
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily oral dosing with oral tablets.
Study: NCT03953144
Drug: IC-Green (ICG)
Normalized name: acid green 50
DrugBank: Indocyanine green acid form (DB09374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Study: NCT06369610
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given abiraterone acetate
Study: NCT04393207
Drug: Liposomal bupivacaine (LB)
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
Study: NCT05009992
Drug: Paxalisib
Normalized name: Paxalisib
DrugBank: Paxalisib (DB15186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06478550
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
Study: NCT06043713
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT06043713
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive IV
Study: NCT04914234
Drug: Atenolol Succinate Oral Tablet
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 50 mg
Study: NCT04914234
Drug: Metoprolol Succinate Oral Tablet
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 100 mg
Study: NCT04544007
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
Study: NCT05089916
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
Study: NCT06538181
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
Study: NCT04931849
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
Study: NCT06109467
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
Study: NCT06109467
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
Study: NCT06109467
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
Study: NCT06109467
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
Study: NCT05020925
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) on Day 1 of each cycle
Study: NCT05020925
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib, po, qd
Study: NCT04734665
Drug: Niraparib-Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Study: NCT05376566
Drug: Hydrochloric Acid (2 M)
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
Study: NCT05205486
Drug: Cefazolin 3gm for Injection USP and Dextrose Injection USP
Normalized name: vasopressin (USP) Injection
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg
Study: NCT05321069
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550
Study: NCT04659603
Drug: tusamitamab ravtansine
Normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion
Study: NCT04659603
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion
Study: NCT05953038
Drug: Lysergic Acid Diethylamide Tartrate
Normalized name: diethylamine salicylate
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
Study: NCT06419660
Drug: BI 300202
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 300202
Study: NCT06419660
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole
Study: NCT04710732
Drug: Standard Enoxaparin 40 mg once-daily before randomization
Normalized name: lisinopril
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2
Study: NCT04710732
Drug: Standard Enoxaparin 40 mg once-daily after randomization
Normalized name: lisinopril
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
Study: NCT04710732
Drug: Escalated Enoxaparin 30 mg twice-daily after randomization
Normalized name: clindamycin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
Study: NCT05467475
Drug: BI 1819479
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1819479
Study: NCT05467475
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole
Study: NCT05669768
Drug: Pamiparib/Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
Study: NCT05005455
Drug: bevacizumab with new manufacturing process.
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg,I.V.,single dose
Study: NCT05005455
Drug: bevacizumab with old manufacturing process.
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg,I.V.,single dose
Study: NCT05834231
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT05482074
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, twice a day, dosage per protocol, per 28 day cycle
Study: NCT05954286
Drug: Upamostat
Normalized name: Upamostat
DrugBank: Upamostat (DB13052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
Study: NCT04507841
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
Study: NCT05529056
Drug: Atropine Sulfate 01
Normalized name: atropine sulfate 0.01 MG/MG
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 01 ophthalmic solution
Study: NCT05529056
Drug: Atropine Sulfate 02
Normalized name: atropine sulfate 0.02 MG
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 02 ophthalmic solution
Study: NCT05529056
Drug: Atropine Sulfate 03
Normalized name: atropine sulfate 0.03 MG
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 03 ophthalmic solution
Study: NCT04098666
Drug: extended release metformin
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin extended release 500 mg tablets, up to 4 tablets a day
Study: NCT06541067
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose
Study: NCT05162027
Drug: Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
Normalized name: erenumab-aooe 70 MG in 1 mL Prefilled Syringe
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study: NCT05514990
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT05514990
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO, IV, or IM
Study: NCT04750759
Drug: Niclosamide + Camostat
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide will be applied in combination with camostat.
Study: NCT06061536
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG +3TC + TDF（once daily）.
Study: NCT05199662
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
Study: NCT06573970
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
Study: NCT06327685
Drug: Avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib is an oral tyrosine kinase inhibitor.
Study: NCT06327685
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine is a nucleoside metabolic inhibitor given intravenously.
Study: NCT06106022
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05247424
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin at dose of 100 IU /kg body weight
Study: NCT06152653
Drug: n-acetylcystine (NAC)+ albuterol
Normalized name: Albuterol
DrugBank: Cystine (DB00138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.
Study: NCT03128398
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
Study: NCT06466785
Drug: Efepoetin Alfa
Normalized name: Efepoetin alfa
DrugBank: Efepoetin alfa (DB19197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
Study: NCT04521153
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
Study: NCT04521153
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
Study: NCT05756621
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution.
Study: NCT05756621
Drug: Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
Study: NCT06466785
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
Study: NCT05046639
Drug: 10 mL 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine. Crossover treatment 5 days later using image guided sciatic nerve anesthetic block of the contralateral limb with 10 mL preservative-free saline.